Neovascular Age-Related Macular Degeneration (nAMD)
KLRSKalaris TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for TH103 in Neovascular Age-Related Macular Degeneration (nAMD). The expected timing is based on the latest available company guidance and may change.
9/15/25- Ph1b/2 MAD study initiated; topline data in H2 2026. Ph1a SAD data in Q4 2025. 11/12/25:- Ph1a data still expected Q4 2025. 12/17/25:- Initial Ph1a SAD data positive with single-dose efficacy. Ph1b/2 preliminary data expected H2 2026. 01/28/26:- Phase 1 SAD data to be presented at Macula Society on February 26, 2026. 03/17/26:- Ph1a SAD data detailed; Ph1b/2 preliminary data now expected H1 2027; plan Ph3 start by YE 2027. 05/12/26:- Patient screening underway in Ph1b/2 MAD; prelim data still expected H1 2027; Ph3 start YE 2027. 06/12/26:- Ph1a SAD data to be presented at CTS 2026 on June 13, 2026. 06/23/26:- Phase 1a data to be presented at ASRS on July 17, 2026. Ph1b/2 enrolling; initial data still H1 2027. 07/17/26:- Expanded Ph1a SAD data positive at ASRS 2026; Ph1b/2 MAD enrollment ongoing; initial data still H1 2027. 08/11/26:- Ph1b/2 dosing continues. Preliminary data H1 2027. Potential Ph3 start YE 2027.
Verification
Confirm timing and program details against the company announcement or filing.